Colleges, School and Institutes
Professor Arri Coomarasamy received his undergraduate medical training from the University of Birmingham (1995), and completed his subspecialist training in reproductive medicine and surgery at Guy’s Hospital, London. He gained his MD in 2004 for work exploring the integration of diagnostic and therapeutic information. He now leads a team that continues to move from strength to strength in the development of early pregnancy and global women’s health research.
Professor Arri Coomarasamy’s research has two aims, one to prevent miscarriages and the other to stop mothers dying during childbirth.
One in 4 pregnancies end in a miscarriage, causing untold amount of devastation to couples. In his role as the Director of the Tommy’s National Centre for Miscarriage Research, Arri leads a world-class team of scientists and doctors, researching to stop the occurrence of miscarriages.
Every 2 minutes a mother dies during childbirth somewhere in the world, often in the prime of her life and often leaving behind a young family. A third of these deaths are from post-partum haemorrhage (excessive bleeding at childbirth). In his role as the Director of the WHO Collaborating Centre for Global Women’s Health, Arri leads an international team of researchers focused on finding ways to prevent women dying from excessive bleeding at childbirth.
His research portfolio includes numerous national and international multicentre randomised controlled trials, including:
- The PROMISE Trial (NEJM, 2015), exploring the role of progesterone in women with unexplained recurrent miscarriages,
- The WHO CHAMPION Trial (NEJM, 2018), studying the effects of heat-stable carbetocin to prevent postpartum haemorrhage,
- The TABLET Trial (NEJM, 2019), evaluating the effects of levothyroxine therapy to prevent miscarriages in women with thyroid antibodies,
- The AIMS Trial (NEJM, 2019), assessing the effects of prophylactic antibiotics before miscarriage surgery in low-income countries,
- The PRISM Trial (NEJM, 2019), evaluating the effects of progesterone therapy for women with early pregnancy bleeding,
- The MifeMiso Trial (ongoing), exploring the role of misoprostol with or without mifepristone in the medical management of missed miscarriages,
- The LOCI Trial (ongoing), studying the effects of letrozole versus clomifene, with or without metformin, for ovulation induction in women with polycystic ovary syndrome,
- The E-MOTIVE Trial (ongoing), exploring the effects of early detection and first-response management of postpartum haemorrhage with a bundle of care in low resource countries.
Professor Coomarasamy is also a co-investigator in several clinical trials, including:
- Surgical Evacuation with intraopErative Ultrasound: a pilot trial to assess feasibility (The SEE U Trial)
- Chronic Endometritis and Recurrent Miscarriage (The CERM Trial)
- Pilot trial of Antioxidant Therapy in Men with Unexplained Miscarriage (The pAToMiUM Trial),
- A multicentre trial of outpatient hysteroscopy before IVF, after recurrent IVF failures (The TROPHY Trial, Lancet 2016)
- Selection of sperm for assisted reproductive treatment by prior hyaluronic acid binding: increasing live birth outcomes and reducing miscarriage rates – multicentre randomised controlled, blinded trial (The HABSelect Trial, Lancet 2019).
Professor Coomarasamy has significant expertise in effectiveness and test accuracy data meta-analysis techniques, including advanced data synthesis approaches such as network meta-analysis, meta-regression and bivariate meta-analysis. His work with Professor Zamora (Madrid, Spain) resulted in the first most comprehensive data synthesis software for test accuracy data, Metadisc, which was made available free of charge to researchers worldwide. The software has been cited in the Lancet, JAMA, BMJ and other journal articles more than 1400 times.
Professor Arri Coomarasamy has published over 190 medical articles in high impact journals such as the New England Journal of Medicine, the Lancet, the British Medical Journal and the Cochrane Database of Systematic Reviews.
Professor Coomarasamy takes particular pride in mentoring junior doctors and researchers. He considers it a duty and privilege to support the next generation of academic and clinical investigators and several of his trainees have become outstanding clinicians and researchers. He currently guides a cohort of over twenty doctoral researchers, postdoctoral fellows and clinical lecturers in the fields of gynaecology, early pregnancy care, and global women’s health.
Professor Coomarasamy serves or has in the past served on several international and national committees, including grant funding boards for NIHR, MRC, Wellcome and DfID, the BJOG editorial board, the RCOG Wellbeing of Women Research Panel, various committees of the WHO, the Early Pregnancy Clinical Studies Group, the Reproductive Medicine Clinical Studies Group, and the GLOW organising committee.
Professor Coomarasamy is a founding trustee of Ammalife (www.ammalife.org), an international charity with a mission to find solutions for maternal health problems through practical research and sustainable projects in the developing world. He is an enthusiastic communicator on the theme of research into global women’s health, and frequently delivers talks and seminars on this theme to a range of groups at local and national levels.
Willingness to take PhD students
Arri Coomarasamy specialises in reproductive medicine and surgery. He is also a consultant gynaecologist at Birmingham Women’s Hospital NHS Foundation Trust. His research interests encompass:
Tubal Infertility Research
Global heath research (obstetrics; maternal mortality reduction)
Professor Coomarasamy supervises MD and PhD in all his areas of interest.